NASDAQ:SGHT Sight Sciences (SGHT) Stock Price, News & Analysis → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free SGHT Stock Alerts $5.55 -0.10 (-1.77%) (As of 05/8/2024 ET) Add Compare Share Share Today's Range$5.46▼$5.7450-Day Range$4.02▼$6.1052-Week Range$1.04▼$10.70Volume73,486 shsAverage Volume213,307 shsMarket Capitalization$275.00 millionP/E RatioN/ADividend YieldN/APrice Target$4.70 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Sight Sciences alerts: Email Address Sight Sciences MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside15.3% Downside$4.70 Price TargetShort InterestHealthy4.75% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.07Based on 13 Articles This WeekInsider TradingSelling Shares$173,375 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.04) to ($0.95) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.64 out of 5 starsMedical Sector837th out of 905 stocksSurgical & Medical Instruments Industry88th out of 95 stocks 1.0 Analyst's Opinion Consensus RatingSight Sciences has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 5 hold ratings, and 1 sell rating.Amount of Analyst CoverageSight Sciences has only been the subject of 2 research reports in the past 90 days.Read more about Sight Sciences' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted4.75% of the float of Sight Sciences has been sold short.Short Interest Ratio / Days to CoverSight Sciences has a short interest ratio ("days to cover") of 6.8.Change versus previous monthShort interest in Sight Sciences has recently decreased by 2.33%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldSight Sciences does not currently pay a dividend.Dividend GrowthSight Sciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SGHT. Previous Next 2.3 News and Social Media Coverage News SentimentSight Sciences has a news sentiment score of 0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.36 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Sight Sciences this week, compared to 2 articles on an average week.Search Interest1 people have searched for SGHT on MarketBeat in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sight Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $173,375.00 in company stock.Percentage Held by Insiders27.10% of the stock of Sight Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions55.51% of the stock of Sight Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Sight Sciences' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Sight Sciences are expected to grow in the coming year, from ($1.04) to ($0.95) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sight Sciences is -4.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sight Sciences is -4.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSight Sciences has a P/B Ratio of 2.25. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Sight Sciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… About Sight Sciences Stock (NASDAQ:SGHT)Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. It also offers TearCare System, a wearable eyelid technology for adult patients with evaporative dry eye disease due to meibomian gland dysfunction, as well as related components. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California.Read More SGHT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SGHT Stock News HeadlinesMay 7, 2024 | americanbankingnews.comSight Sciences (NASDAQ:SGHT) Rating Reiterated by Needham & Company LLCMay 6, 2024 | finance.yahoo.comSight Sciences, Inc. (NASDAQ:SGHT) Q1 2024 Earnings Call TranscriptMay 9, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.May 5, 2024 | americanbankingnews.comPiper Sandler Reiterates Neutral Rating for Sight Sciences (NASDAQ:SGHT)May 5, 2024 | americanbankingnews.comSight Sciences, Inc. (NASDAQ:SGHT) Given Average Recommendation of "Hold" by BrokeragesMay 4, 2024 | finance.yahoo.comSight Sciences First Quarter 2024 Earnings: Revenues Beat Expectations, EPS LagsMay 3, 2024 | finance.yahoo.comQ1 2024 Sight Sciences Inc Earnings CallMay 2, 2024 | investorplace.comSGHT Stock Earnings: Sight Sciences Misses EPS, Beats Revenue for Q1 2024May 9, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.May 2, 2024 | globenewswire.comSight Sciences Reports First Quarter 2024 Financial Results and Reaffirms Full Year 2024 Financial GuidanceMay 1, 2024 | markets.businessinsider.comSight Sciences earnings preview: what to expectApril 29, 2024 | globenewswire.comSight Sciences Announces Successful $34 Million Patent Infringement Verdict Against Alcon and its Hydrus Microstent for Microinvasive Glaucoma SurgeryApril 22, 2024 | finance.yahoo.comWith 34% ownership, Sight Sciences, Inc. (NASDAQ:SGHT) has piqued the interest of institutional investorsApril 18, 2024 | globenewswire.comSight Sciences to Report First Quarter Financial Results on May 2, 2024April 12, 2024 | investing.comSight Sciences reports glaucoma surgery study resultsApril 10, 2024 | globenewswire.comSight Sciences Announces the Publication of Large-Scale, Real-World MIGS Study Demonstrating the Comprehensive Aqueous Outflow Restorative Procedure with OMNI® Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2 Years in Patients with GlaucomaApril 2, 2024 | globenewswire.comSight Sciences Announces the Results of the Three-Year Prospective GEMINI Trial and the Cross-Over Phase of the SAHARA RCT at the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual MeetingMarch 27, 2024 | finance.yahoo.comSight Sciences to Present at the Upcoming 23rd Annual Needham Healthcare ConferenceMarch 26, 2024 | globenewswire.comSight Sciences to Present at the Upcoming 23rd Annual Needham Healthcare ConferenceMarch 16, 2024 | finance.yahoo.comSGHT Apr 2024 5.000 callMarch 8, 2024 | finance.yahoo.comSight Sciences, Inc. (NASDAQ:SGHT) Q4 2023 Earnings Call TranscriptMarch 8, 2024 | finance.yahoo.comQ4 2023 Sight Sciences Inc Earnings CallMarch 7, 2024 | finance.yahoo.comSight Sciences Inc (SGHT) Navigates Challenges to Maintain Revenue Growth and Reduce ExpensesMarch 7, 2024 | investorplace.comSGHT Stock Earnings: Sight Sciences Beats EPS, Misses Revenue for Q4 2023March 7, 2024 | benzinga.comSight Sciences: Q4 Earnings InsightsMarch 7, 2024 | msn.comSight Sciences GAAP EPS of -$0.22 beats by $0.12, revenue of $18.8M misses by $0.6MMarch 7, 2024 | globenewswire.comSight Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Initiates Full Year 2024 Financial GuidanceSee More Headlines Receive SGHT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sight Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/07/2024Today5/08/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:SGHT CUSIPN/A CIK1531177 Webwww.sightsciences.com Phone877-266-1144FaxN/AEmployees214Year FoundedN/APrice Target and Rating Average Stock Price Target$4.70 High Stock Price Target$6.00 Low Stock Price Target$4.00 Potential Upside/Downside-15.3%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($1.12) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-55,550,000.00 Net Margins-67.18% Pretax Margin-68.39% Return on Equity-42.84% Return on Assets-31.07% Debt Debt-to-Equity Ratio0.26 Current Ratio13.29 Quick Ratio12.65 Sales & Book Value Annual Sales$81.06 million Price / Sales3.39 Cash FlowN/A Price / Cash FlowN/A Book Value$2.47 per share Price / Book2.25Miscellaneous Outstanding Shares49,550,000Free Float36,124,000Market Cap$275.00 million OptionableOptionable Beta2.73 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Paul Badawi (Age 49)Co-Founder, President, CEO & Director Comp: $920.3kDr. David Badawi M.D. (Age 54)Founder, CTO & Director Mr. Sam Boong Park (Age 63)Chief Operating Officer Comp: $531.78kMs. Alison Perry Bauerlein (Age 43)CFO & Treasurer Mr. Jeremy B. Hayden (Age 54)Chief Legal Officer Mr. Steve R. Tamayo Jr.VP and Chief Ethics & Compliance OfficerDr. Reay H. BrownChief Medical OfficerTom HuangHead of Corporate Strategy & DevelopmentMr. Matthew W. Link (Age 49)Chief Commercial Officer Mr. Stephen B. Thau J.D.SecretaryMore ExecutivesKey CompetitorsInovio PharmaceuticalsNASDAQ:INOTriSalus Life SciencesNASDAQ:TLSIFractyl HealthNASDAQ:GUTSUtah Medical ProductsNASDAQ:UTMDAngioDynamicsNASDAQ:ANGOView All CompetitorsInsiders & InstitutionsMirae Asset Global Investments Co. Ltd.Bought 9,106 shares on 5/1/2024Ownership: 0.054%Paul BadawiSold 12,571 sharesTotal: $63,860.68 ($5.08/share)David BadawiSold 3,128 sharesTotal: $15,890.24 ($5.08/share)Alison BauerleinSold 10,123 sharesTotal: $51,424.84 ($5.08/share)Sam Boong ParkSold 3,414 sharesTotal: $17,343.12 ($5.08/share)View All Insider TransactionsView All Institutional Transactions SGHT Stock Analysis - Frequently Asked Questions Should I buy or sell Sight Sciences stock right now? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sight Sciences in the last year. There are currently 1 sell rating, 5 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" SGHT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SGHT, but not buy additional shares or sell existing shares. View SGHT analyst ratings or view top-rated stocks. What is Sight Sciences' stock price target for 2024? 7 analysts have issued 1-year price targets for Sight Sciences' stock. Their SGHT share price targets range from $4.00 to $6.00. On average, they anticipate the company's stock price to reach $4.70 in the next twelve months. This suggests that the stock has a possible downside of 15.3%. View analysts price targets for SGHT or view top-rated stocks among Wall Street analysts. How have SGHT shares performed in 2024? Sight Sciences' stock was trading at $5.16 at the beginning of the year. Since then, SGHT stock has increased by 7.6% and is now trading at $5.55. View the best growth stocks for 2024 here. Are investors shorting Sight Sciences? Sight Sciences saw a decrease in short interest in March. As of March 31st, there was short interest totaling 1,290,000 shares, a decrease of 20.9% from the March 15th total of 1,630,000 shares. Based on an average trading volume of 215,100 shares, the days-to-cover ratio is presently 6.0 days. Approximately 4.9% of the company's shares are short sold. View Sight Sciences' Short Interest. When is Sight Sciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our SGHT earnings forecast. How were Sight Sciences' earnings last quarter? Sight Sciences, Inc. (NASDAQ:SGHT) posted its earnings results on Thursday, March, 7th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.13. The company earned $18.75 million during the quarter, compared to analyst estimates of $18.70 million. Sight Sciences had a negative trailing twelve-month return on equity of 42.84% and a negative net margin of 67.18%. During the same quarter in the previous year, the business earned ($0.35) EPS. What guidance has Sight Sciences issued on next quarter's earnings? Sight Sciences issued an update on its FY 2024 earnings guidance on Friday, May, 3rd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $81.0 million-$85.0 million, compared to the consensus revenue estimate of $82.5 million. When did Sight Sciences IPO? Sight Sciences (SGHT) raised $150 million in an IPO on Thursday, July 15th 2021. The company issued 6,980,000 shares at $20.00-$23.00 per share. Who are Sight Sciences' major shareholders? Sight Sciences' stock is owned by a variety of institutional and retail investors. Top institutional investors include Mirae Asset Global Investments Co. Ltd. (0.05%). Insiders that own company stock include Alison Bauerlein, D1 Capital Partners LP, David Badawi, Jeremy B Hayden, Jesse Selnick, Paul Badawi, Sam Boong Park and Staffan Encrantz. View institutional ownership trends. How do I buy shares of Sight Sciences? Shares of SGHT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SGHT) was last updated on 5/9/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDems have chosen Biden replacement?Paradigm PressObama’s Forever Term [exposed]Porter & CompanyThe A.I. story nobody is telling you (Read ASAP)TradeSmithGold Set to EXPLODE!Gold Safe ExchangeExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sight Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
